These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3021709)

  • 1. In-vitro activity of cefoperazone-sulbactam against Bacteroides species.
    Souza Dias MB; Jacobus NV; Tally FP
    J Antimicrob Chemother; 1986 Oct; 18(4):467-71. PubMed ID: 3021709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.
    Crosby MA; Gump DW
    Antimicrob Agents Chemother; 1982 Sep; 22(3):398-405. PubMed ID: 6291451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
    Jones RN; Barry AL; Thornsberry C; Wilson HW
    Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefoperazone/sulbactam and other antimicrobials against anaerobic bacteria.
    D'Amato RF; Hochstein L; Frankel H
    Diagn Microbiol Infect Dis; 1990; 13(1):51-5. PubMed ID: 2331850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.
    Jones RN; Wilson HW; Thornsberry C; Barry AL
    Diagn Microbiol Infect Dis; 1985 Nov; 3(6):489-99. PubMed ID: 2998694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
    Appelbaum PC; Spangler SK; Jacobs MR
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Mar; 32(3):403-6. PubMed ID: 3364960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.
    Barry AL; Jones RN
    J Clin Microbiol; 1988 Jan; 26(1):13-7. PubMed ID: 3343304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of cefsulodin combined with cefoxitin and sulbactam against Bacteroides species.
    Fu KP; Kimble EF; Zoganas H; Konopka EA
    J Antimicrob Chemother; 1984 Mar; 13(3):257-65. PubMed ID: 6327598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
    Rezvan SP; Sidorenko SV; Budanov SV
    Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentre study on antibiotic susceptibilities of anaerobic bacteria to cefoperazone-sulbactam and other antimicrobial agents.
    Clark RB; Bartelt MA; Chan EL; Dalton HP
    J Antimicrob Chemother; 1992 Jan; 29(1):57-67. PubMed ID: 1737725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefoperazone and cefoperazone-sulbactam susceptibility tests with anaerobic bacteria by the thioglycolate disk elution method.
    Barry AL; Packer RR; Jones RN
    J Clin Microbiol; 1985 Nov; 22(5):882-3. PubMed ID: 2997274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
    Barry AL; Jones RN; Packer RR
    J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative in-vitro activity of cefoperazone/sulbactam and 11 other agents against multidrug resistant Bacteroides fragilis group species.
    Goldstein EJ; Citron DM
    J Antimicrob Chemother; 1996 Oct; 38(4):733-7. PubMed ID: 8937969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
    Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
    New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.
    Wexler HM; Harris B; Carter WT; Finegold SM
    Antimicrob Agents Chemother; 1985 May; 27(5):876-8. PubMed ID: 2990330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparison of cefoperazone/sulbactam with selected antimicrobials against 300 bacteroides isolates. Inhibitory activity and time-kill kinetic studies.
    Gelfand MS; Grogan JT; Haas MJ
    Diagn Microbiol Infect Dis; 1989; 12(5):421-8. PubMed ID: 2612130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
    Hedberg M; Lindqvist L; Tunér K; Nord CE
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.